Novartis Gene Therapies
UEI: H1YRZN8TQBC3
• CAGE: 8BDQ4
Overview
Parent Awardee
Company Description
Learn what cell and gene therapy is, how it differs from conventional medicine, and why it's creating a new turning point in how we treat disease.
Name
Novartis Gene Therapies
Website
Headquarters
Deerfield, IL
United States
United States
Federal recipient
NOVARTIS GENE THERAPIES INC
(UEI H1YRZN8TQBC3, CAGE 8BDQ4)
is headquartered in Deerfield IL.
Its primary registered NAICS is 325412 Pharmaceutical Preparation Manufacturing.
The corporation
was founded in March 2010 and
federally registered in
February 2019.
Federal Registration and Certifications
Legal Name
NOVARTIS GENE THERAPIES INC
UEI
H1YRZN8TQBC3
CAGE Code
8BDQ4
Primary NAICS
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
March 10, 2010
Initial Registration
Feb. 14, 2019
Last Registration
Feb. 25, 2025
Registration Activation
Feb. 25, 2025
Registration Expiration
Feb. 21, 2026
Fiscal Year End
December 31
Reported Entity Types
Foreign Owned
For Profit Organization
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
501-750
Reported NAICS
Accepts Credit Cards
No
People
Vendor contacts at Novartis Gene Therapies
GSA Schedules and Price Lists
- Novartis Gene Therapies
- PoP: 9/14/20 - 9/14/26
- Type: Pharmaceuticals and Drugs (FSS 65 I B)
- Novartis Gene Therapies
- PoP: 10/2/19 - 9/2/20 (Ended)